APA (7th ed.) Citation

R, M., D, R., MG, P., C, A., R, I., V, C., . . . C, C. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European journal of cancer (Oxford, England : 1990), 222, 115470. https://doi.org/10.1016/j.ejca.2025.115470

Chicago Style (17th ed.) Citation

R, Moretto, et al. "The Relative Dose Intensity of First-line FOLFOXIRI and FOLFOX/FOLFIRI Both in Combination with Bevacizumab Affects Prognosis of Metastatic Colorectal Cancer Patients: A Pooled Analysis of TRIBE and TRIBE2 Studies." European Journal of Cancer (Oxford, England : 1990) 222 (2025): 115470. https://doi.org/10.1016/j.ejca.2025.115470.

MLA (9th ed.) Citation

R, Moretto, et al. "The Relative Dose Intensity of First-line FOLFOXIRI and FOLFOX/FOLFIRI Both in Combination with Bevacizumab Affects Prognosis of Metastatic Colorectal Cancer Patients: A Pooled Analysis of TRIBE and TRIBE2 Studies." European Journal of Cancer (Oxford, England : 1990), vol. 222, 2025, p. 115470, https://doi.org/10.1016/j.ejca.2025.115470.